pre-miRNA Information | |
---|---|
pre-miRNA | hsa-mir-497 |
Genomic Coordinates | chr17: 7017911 - 7018022 |
Synonyms | MIRN497, hsa-mir-497, MIR497 |
Description | Homo sapiens miR-497 stem-loop |
Comment | None |
RNA Secondary Structure | |
Associated Diseases |
Mature miRNA Information | |||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mature miRNA | hsa-miR-497-3p | ||||||||||||||||||||||||||||
Sequence | 64| CAAACCACACUGUGGUGUUAGA |85 | ||||||||||||||||||||||||||||
Evidence | Experimental | ||||||||||||||||||||||||||||
Experiments | Cloned | ||||||||||||||||||||||||||||
Editing Events in miRNAs |
|
||||||||||||||||||||||||||||
SNPs in miRNA |
|
||||||||||||||||||||||||||||
Putative Targets |
miRNA Expression profile | |
---|---|
Human miRNA Tissue Atlas | |
Circulating MicroRNA Expression Profiling |
Gene Information | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gene Symbol | MDFIC | ||||||||||||||||||||
Synonyms | HIC, MDFIC1 | ||||||||||||||||||||
Description | MyoD family inhibitor domain containing | ||||||||||||||||||||
Transcript | NM_001166345 | ||||||||||||||||||||
Other Transcripts | NM_001166346 , NM_199072 | ||||||||||||||||||||
Expression | |||||||||||||||||||||
Putative miRNA Targets on MDFIC | |||||||||||||||||||||
3'UTR of MDFIC (miRNA target sites are highlighted) |
>MDFIC|NM_001166345|3'UTR 1 ATATTTATCTTTTGTTTGTGTTAAAACTGGAGAGTGTTTAAAAATTTCCTTTTGGGGGGAAGAAAAGCACATTGTAAGAT 81 TCTCATGAAACAACATGGAATTTGCACTGTTAACTCATTATTGTAAGTAATCTCTGAAAGCCTTTTTACTTTAACCAAAT 161 CTACATGGTTTAATATGTGAAATTTTAACTACTTTAACTAGTTTTATAAATTTCTTAATATGTTACAATAACTTAGGGAC 241 ATTTTGACACCCCCCTTCCCAAATGTTAAATGCCTTCTCCTTTTTACCGATATTTCTGTTTCTTTTAACCGTTCTCAGGA 321 GCACTTTGCTCCAAATATATTATTTTTCAGTGTGTATTTAAACGAGGCAGTTTATTTTGATATGTATCTATTCATGATTG 401 AAAGGAAGCAGTCTTGGCCAGGCACGGTGGCTTACACCTGTAACCCTGGCATTTTGGGAGGCCAAGGTGGGCAGATTGCC 481 TGAGCTCAGGAGTTCGAGACCAGCCAGGGCAACATGGTGAAACCCCATCTCTACTAAAATACAAAAAGTTAGCTGGGCTT 561 GGCGGTGTGCGCCTGTAGTCCCAGCTACTCAGGAGGCTGAGGCAGGAGAATTGCTTGAACCCGAGAGGCGGAAGTTGCAG 641 TGAGCCGAGATTGTGCCACTGAACTCCAACCTGCACTCCAGCCTGGGCAACAGAGCGAGACTCCATCTCTAAATAAATAA 721 ATAAATAAATAAATAAATAAATAAATAAATAAACAAACCAGTCTTTATTTTAAAAGAAACTTTAGGAAACAAACCCACAT 801 AATAGTTGGGAACCAGTGTTGATCTCTCTCCCTTACCTTCTCCACTTGTTCAACAGACTCTGAATGCCGACTGTGTGGAC 881 TCTCTTCCTCAGACTGTGGGGACAGATACAATTCCACTCCTGTCCACAGGAACATGAGATTTAGCAGACTAAGGAGATCT 961 GTAAAGAATGAACCATACCACAAGGCATACTGAAGTGAGGATTATAAGAGAAATAAACTCAAAATGCTGTTGGAATATGC 1041 AGAGAATTGCTACCAGAATATTCAGTAAGGTTTCAGGGAGAATGTGGCATTTGAGGACTCTCTTAGAATGAGTGATTCAC 1121 CTGCTATTTAAATGAATTATTTAGATTTTTGACAAAGATTTAGGTGGACACCCTAAACTGTGTGTGCCTTTAACCAGTTA 1201 AAAGAACAGTGCCTTCAGCATACTTTTTTATTAGTTGTAGGAATACAGCTTTTTGAAAAAGCTATAAAGTTTAAATTAAC 1281 TAAAAATATGCATTTTCTTACACATAATTTAAATGTTATCATACTTTTTTGATGAAAACATAATGCCTTAGTAAAATAGC 1361 TCTATTTAATAAAGAAGATTGAGTACTCTGACACATTTCATTTAAATTAGGAAATTTTTAATATTAAAATCCCAGTGTTC 1441 TGAGTTATTGAAAGGCTTTCTTTTATTTTGAGAGCTTTAGGTCTTTTTGGGATGAGAACATTTTAGTTGTTTAGTTTGTT 1521 TCTTAAGCAGTGCTATTTTTTGTAAACACAGATAAATGGAAACCATTCTTTTCAATGCAGAAGAAATCTAGATATCCCCT 1601 ACTGTGACCAAATTTCTGTATTACGATTTTATGTTAAATTAAACTAATATGGCAGGTTATAATGATCCTTAAGTGTAAAG 1681 AAATCAGTCAATTACAAGAGTAATTGTATAGTTATTGAGACCTATAGTGTGTGGCTTAGATGAAAGGGAGAGTAAATTTT 1761 CATACCATGCTCTCTCCTACTCAGTTTGATCTCTCTAAAATTGTAGTTTGGTTTGATTTAATATAATTCTTAGTAGAAAT 1841 TTTGAAAGTATGCTTTGGGATTAATAATTATTTTTAATTTTTCTGGCTGAATATCAAATTGATAGTAACAACAGAAGCAT 1921 AATTTTAGGAAGGCTTTCGCAAACCTAGCCTTTTAAGAGAGGTTTTTAACCTGAAGCATGAGAATATATCACCTGTGGTT 2001 TTTCCTTTGAGATGAAACGTAGTTTCTAGTTATATCATTACTTAAAGGGCTTAAAAAGAAAAAACTTAGCAAACTTTTGA 2081 ATCTTTCTTTTATTGCTATTTACACATACATACACACATACAAAACCTTTAAATTTTGGGATCTGAATATAATTCTGGTA 2161 AACAGCTGTCTTCATTTTTCTCCTCTAAAGAACTTAATTCATTTGTTACATAAAATATAAGGAAATCTTTATACTATTTT 2241 ACAGTAACCACAATCTAAATATTTACATATACCCAAAATTAACTTATGCTCATATATTAGGATGTGAGAATATCATCTGT 2321 TTATGGACACATGAAACCTCCTAATGACCTGGAATTGTTAGAATATTTGACTTTTTATATGCAAAGTTTTTCAACCAAGT 2401 GGTTTGTCTAATATTTAAACATGTACTGGCACAATTTGTGATGAAAATATTAGCACATTTGCAATAATGTTTCTCCATAA 2481 CAGAGAATGTTAATGGATACCAGAATTTTATTTTTGTATTTATGTTCATAGTACTTTTCCTCTTGTCTACTCCAGACAGT 2561 TATTCCATAAAGCATTTGTATAATTAAAAGGAAAACAGAAAAAGGAAAAGTAGGCAAATGTGAAAATAGTTTCAATATAT 2641 CTTATGATTTCTTAATGTAAAATGTTTTGTTGAAGTATATGGCTATCATGACTAAGTGCTAGAATTTATAGTTACAGGCG 2721 GTGTCCTTTTAAATGTGGAAAGGCTTTTAAAATATTTTAAAACTGGACCTGTATTATCCTGAATACACTATTTTGAAAAT 2801 TTTTAAAAATGACTTCTTTATTTTGCTTTACCGTATGTTTATATCTAATTGACATATTGACTAATGTTTGAAAGAATTCA 2881 ACCATAAGTTAAAATCTGAAGGTTATCTTTATCATGTTTCATCCCTGTCTGAAGATTTCCTAGTCTTCTTATGTAAATCA 2961 CATGACTCATGTCCGTAAATGAACTATGAAAGATATCGATCAGTTTATGATCATTGACATGTGATTTCAAAACACAGTGT 3041 TCTTTTAAAAATCTATAATATGTCAAAATACAAGTTTTTTTTTTTTACATCGTTTTAGTAAGTTAATTTCATTTATTTAC 3121 TTTGGAGCTATATTTCCACTTAGAAAAACTAAGGTAATTTTACAATATATGCTGAGATTAAAAACCAAGGTAAAAATGAT 3201 CAAACATATATGAAATTGAGTCTTAGATTTAATGAATTTCACTCGAAAATAAATGATCAGAAGAATTTTCATCTAAGGCA 3281 TAGAGTGGCGAAATTTTTGTAAATGCTCGCAGTTAGCATCTAACTAAAACAATACAGTATGACTTTATTTAGGAGAAGGC 3361 TTTTTATTTAGAAAATTATTTTTTCATTTTTACAGTGTATCAACTGTATCCATTTTCCTCACCTGGATAGTCAATGTTAT 3441 CTGAGCAGTTCAAGGAGTAACCAAGGCAACCTTATGTAATAACTTTCCATTCTTTATCCATACAAACTCTTTCAGTGCCC 3521 TAGATTCTAATGTTATAAACGTCAAACATCACTGCCCAACATAAATAAGACTCGAGACTTATTAACATAAATAAGTATCT 3601 TGCCTTCTTGAATGCTAGTTAAATGCTTAGATTTACCTAACTGCCTAATGAATCAGGTTATTTGTTAATAAGATTATTTT 3681 TCAAATTATTTAAGACCTTTATGCCCCTTCCAATTACTTGTGATTTGTAGGCCTGTAGGATTGTTGCATCTAATCTGACT 3761 GGCAACAGAAAATGTCATCAAATACTATAATATCCATTTTGTTTTCTTTTGCACTAATACAACAGAACATATCATTTTTG 3841 TTTTAAACAATGGTTAATATATTAATAGGGTTTGTTCCACACTTACTATTTATAGTTTTTATAATCAAGCATTGGGTATT 3921 AAAAGAGAATCCTTTCAACCCTTCATCTTCGTATGCTTATACAATAAATTGCAGTGAGTGT Target sites
Provided by authors
Predicted by miRanda
DRVs
SNPs
DRVs & SNPs
|
||||||||||||||||||||
miRNA-target interactions (Predicted by miRanda) |
|
||||||||||||||||||||
DRVs in gene 3'UTRs | |||||||||||||||||||||
SNPs in gene 3'UTRs |
Experimental Support 1 for Functional miRNA-Target Interaction | |
---|---|
miRNA:Target | ---- |
Validation Method |
|
Conditions | C8166 |
Location of target site | 3'UTR |
Tools used in this research | TargetScan , miRTarCLIP , Piranha |
Original Description (Extracted from the article) |
...
PAR-CLIP data was present in GSM1462572. RNA binding protein: AGO2. Condition:C8166 NL4-3
... - Whisnant AW; Bogerd HP; Flores O; Ho P; et al., 2013, mBio. |
Article |
- Whisnant AW; Bogerd HP; Flores O; Ho P; et al. - mBio, 2013
UNLABELLED: The question of how HIV-1 interfaces with cellular microRNA (miRNA) biogenesis and effector mechanisms has been highly controversial. Here, we first used deep sequencing of small RNAs present in two different infected cell lines (TZM-bl and C8166) and two types of primary human cells (CD4(+) peripheral blood mononuclear cells [PBMCs] and macrophages) to unequivocally demonstrate that HIV-1 does not encode any viral miRNAs. Perhaps surprisingly, we also observed that infection of T cells by HIV-1 has only a modest effect on the expression of cellular miRNAs at early times after infection. Comprehensive analysis of miRNA binding to the HIV-1 genome using the photoactivatable ribonucleoside-induced cross-linking and immunoprecipitation (PAR-CLIP) technique revealed several binding sites for cellular miRNAs, a subset of which were shown to be capable of mediating miRNA-mediated repression of gene expression. However, the main finding from this analysis is that HIV-1 transcripts are largely refractory to miRNA binding, most probably due to extensive viral RNA secondary structure. Together, these data demonstrate that HIV-1 neither encodes viral miRNAs nor strongly influences cellular miRNA expression, at least early after infection, and imply that HIV-1 transcripts have evolved to avoid inhibition by preexisting cellular miRNAs by adopting extensive RNA secondary structures that occlude most potential miRNA binding sites. IMPORTANCE: MicroRNAs (miRNAs) are a ubiquitous class of small regulatory RNAs that serve as posttranscriptional regulators of gene expression. Previous work has suggested that HIV-1 might subvert the function of the cellular miRNA machinery by expressing viral miRNAs or by dramatically altering the level of cellular miRNA expression. Using very sensitive approaches, we now demonstrate that neither of these ideas is in fact correct. Moreover, HIV-1 transcripts appear to largely avoid regulation by cellular miRNAs by adopting an extensive RNA secondary structure that occludes the ability of cellular miRNAs to interact with viral mRNAs. Together, these data suggest that HIV-1, rather than seeking to control miRNA function in infected cells, has instead evolved a mechanism to become largely invisible to cellular miRNA effector mechanisms.
LinkOut: [PMID: 23592263]
|
CLIP-seq Support 1 for dataset GSM1462572 | |
---|---|
Method / RBP | PAR-CLIP / AGO2 |
Cell line / Condition | C8166 / C8166 NL4-3 |
Location of target site | ENST00000393486.1 | 3UTR | CCUUUUUACUUUAACCAAAUCUACAUG |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 23592263 / GSE59944 |
CLIP-seq Viewer | Link |
MiRNA-Target Expression Profile | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
MiRNA-Target Expression Profile (TCGA) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
95 hsa-miR-497-3p Target Genes:
Functional analysis:
ID | Target | Description | Validation methods | |||||||||
Strong evidence | Less strong evidence | |||||||||||
MIRT092955 | CYP2U1 | cytochrome P450 family 2 subfamily U member 1 | 2 | 4 | ||||||||
MIRT124568 | PRRC2B | proline rich coiled-coil 2B | 2 | 2 | ||||||||
MIRT125196 | EIF1AX | eukaryotic translation initiation factor 1A, X-linked | 2 | 4 | ||||||||
MIRT147296 | KPNA2 | karyopherin subunit alpha 2 | 2 | 8 | ||||||||
MIRT163999 | KIAA1109 | KIAA1109 | 2 | 4 | ||||||||
MIRT252495 | NWD1 | NACHT and WD repeat domain containing 1 | 2 | 2 | ||||||||
MIRT357969 | GRPEL2 | GrpE like 2, mitochondrial | 2 | 2 | ||||||||
MIRT443007 | TRIOBP | TRIO and F-actin binding protein | 2 | 2 | ||||||||
MIRT443524 | NETO1 | neuropilin and tolloid like 1 | 2 | 2 | ||||||||
MIRT443573 | EVX2 | even-skipped homeobox 2 | 2 | 2 | ||||||||
MIRT443656 | BACH1 | BTB domain and CNC homolog 1 | 2 | 2 | ||||||||
MIRT460670 | KRT10 | keratin 10 | 2 | 8 | ||||||||
MIRT464761 | UBE2N | ubiquitin conjugating enzyme E2 N | 2 | 2 | ||||||||
MIRT465032 | LINC00598 | long intergenic non-protein coding RNA 598 | 2 | 2 | ||||||||
MIRT465040 | TTC39C | tetratricopeptide repeat domain 39C | 2 | 2 | ||||||||
MIRT468667 | SEC62 | SEC62 homolog, preprotein translocation factor | 2 | 2 | ||||||||
MIRT473694 | MAPK8 | mitogen-activated protein kinase 8 | 2 | 4 | ||||||||
MIRT477618 | EFNA3 | ephrin A3 | 2 | 2 | ||||||||
MIRT480506 | C11orf57 | chromosome 11 open reading frame 57 | 2 | 2 | ||||||||
MIRT480592 | BUB3 | BUB3, mitotic checkpoint protein | 2 | 2 | ||||||||
MIRT486915 | ZNF398 | zinc finger protein 398 | 2 | 6 | ||||||||
MIRT487770 | ANKEF1 | ankyrin repeat and EF-hand domain containing 1 | 2 | 16 | ||||||||
MIRT493265 | MDFIC | MyoD family inhibitor domain containing | 2 | 2 | ||||||||
MIRT495271 | SLC1A2 | solute carrier family 1 member 2 | 2 | 4 | ||||||||
MIRT495309 | CHST12 | carbohydrate sulfotransferase 12 | 2 | 2 | ||||||||
MIRT496681 | DPP6 | dipeptidyl peptidase like 6 | 2 | 4 | ||||||||
MIRT496891 | FOXP1 | forkhead box P1 | 2 | 2 | ||||||||
MIRT497330 | IRF4 | interferon regulatory factor 4 | 2 | 2 | ||||||||
MIRT498272 | KIAA1644 | KIAA1644 | 2 | 2 | ||||||||
MIRT498634 | CHD4 | chromodomain helicase DNA binding protein 4 | 2 | 10 | ||||||||
MIRT500581 | USP53 | ubiquitin specific peptidase 53 | 2 | 2 | ||||||||
MIRT500751 | TMPPE | transmembrane protein with metallophosphoesterase domain | 2 | 6 | ||||||||
MIRT509668 | ZNF354B | zinc finger protein 354B | 2 | 10 | ||||||||
MIRT510919 | PSMA2 | proteasome subunit alpha 2 | 2 | 4 | ||||||||
MIRT519118 | CEP76 | centrosomal protein 76 | 2 | 2 | ||||||||
MIRT526193 | ABCG2 | ATP binding cassette subfamily G member 2 (Junior blood group) | 2 | 2 | ||||||||
MIRT526746 | HLA-DOB | major histocompatibility complex, class II, DO beta | 2 | 2 | ||||||||
MIRT527270 | FBLN2 | fibulin 2 | 2 | 2 | ||||||||
MIRT528198 | PLEKHM2 | pleckstrin homology and RUN domain containing M2 | 2 | 2 | ||||||||
MIRT528330 | TBC1D22B | TBC1 domain family member 22B | 2 | 2 | ||||||||
MIRT530346 | GABRB3 | gamma-aminobutyric acid type A receptor beta3 subunit | 2 | 2 | ||||||||
MIRT533627 | TMX3 | thioredoxin related transmembrane protein 3 | 2 | 2 | ||||||||
MIRT533738 | TMEM200C | transmembrane protein 200C | 2 | 2 | ||||||||
MIRT533779 | TMEM133 | transmembrane protein 133 | 2 | 2 | ||||||||
MIRT534317 | SKIDA1 | SKI/DACH domain containing 1 | 2 | 2 | ||||||||
MIRT538438 | COG5 | component of oligomeric golgi complex 5 | 2 | 2 | ||||||||
MIRT539156 | AREL1 | apoptosis resistant E3 ubiquitin protein ligase 1 | 2 | 2 | ||||||||
MIRT539474 | ADARB2 | adenosine deaminase, RNA specific B2 (inactive) | 2 | 2 | ||||||||
MIRT539620 | SHISA9 | shisa family member 9 | 2 | 2 | ||||||||
MIRT539650 | BUB1 | BUB1 mitotic checkpoint serine/threonine kinase | 2 | 2 | ||||||||
MIRT540346 | OPHN1 | oligophrenin 1 | 2 | 2 | ||||||||
MIRT540412 | PITPNC1 | phosphatidylinositol transfer protein, cytoplasmic 1 | 2 | 2 | ||||||||
MIRT541200 | HSP90AA1 | heat shock protein 90 alpha family class A member 1 | 2 | 2 | ||||||||
MIRT541395 | CDC27 | cell division cycle 27 | 2 | 2 | ||||||||
MIRT546443 | SNX5 | sorting nexin 5 | 2 | 2 | ||||||||
MIRT547369 | MSI2 | musashi RNA binding protein 2 | 2 | 2 | ||||||||
MIRT553288 | TSPAN3 | tetraspanin 3 | 2 | 2 | ||||||||
MIRT554402 | SERP1 | stress associated endoplasmic reticulum protein 1 | 2 | 2 | ||||||||
MIRT557822 | FOXN2 | forkhead box N2 | 2 | 2 | ||||||||
MIRT568530 | ANP32E | acidic nuclear phosphoprotein 32 family member E | 2 | 2 | ||||||||
MIRT569508 | THYN1 | thymocyte nuclear protein 1 | 2 | 2 | ||||||||
MIRT570707 | FAM69A | family with sequence similarity 69 member A | 2 | 2 | ||||||||
MIRT608376 | PIWIL2 | piwi like RNA-mediated gene silencing 2 | 2 | 2 | ||||||||
MIRT608483 | NKTR | natural killer cell triggering receptor | 2 | 6 | ||||||||
MIRT613533 | TRA2B | transformer 2 beta homolog | 2 | 2 | ||||||||
MIRT616601 | ELP2 | elongator acetyltransferase complex subunit 2 | 2 | 2 | ||||||||
MIRT618166 | DUSP18 | dual specificity phosphatase 18 | 2 | 2 | ||||||||
MIRT632059 | CEP135 | centrosomal protein 135 | 2 | 2 | ||||||||
MIRT647379 | ZDHHC23 | zinc finger DHHC-type containing 23 | 2 | 2 | ||||||||
MIRT648366 | POTED | POTE ankyrin domain family member D | 2 | 2 | ||||||||
MIRT651075 | ZNF518B | zinc finger protein 518B | 2 | 4 | ||||||||
MIRT653618 | SLC30A4 | solute carrier family 30 member 4 | 2 | 2 | ||||||||
MIRT653636 | SLC30A1 | solute carrier family 30 member 1 | 2 | 2 | ||||||||
MIRT654895 | POU2F1 | POU class 2 homeobox 1 | 2 | 2 | ||||||||
MIRT656232 | MFSD6 | major facilitator superfamily domain containing 6 | 2 | 2 | ||||||||
MIRT659880 | CAPRIN1 | cell cycle associated protein 1 | 2 | 2 | ||||||||
MIRT660526 | ARL4C | ADP ribosylation factor like GTPase 4C | 2 | 2 | ||||||||
MIRT666286 | SLC30A3 | solute carrier family 30 member 3 | 2 | 2 | ||||||||
MIRT686808 | SNX2 | sorting nexin 2 | 2 | 4 | ||||||||
MIRT695302 | TK1 | thymidine kinase 1 | 2 | 2 | ||||||||
MIRT699737 | SERINC3 | serine incorporator 3 | 2 | 2 | ||||||||
MIRT700794 | PIAS2 | protein inhibitor of activated STAT 2 | 2 | 2 | ||||||||
MIRT712270 | PPP1CB | protein phosphatase 1 catalytic subunit beta | 2 | 2 | ||||||||
MIRT712617 | KNSTRN | kinetochore localized astrin/SPAG5 binding protein | 2 | 2 | ||||||||
MIRT714264 | RPL10A | ribosomal protein L10a | 2 | 2 | ||||||||
MIRT715072 | TMTC1 | transmembrane and tetratricopeptide repeat containing 1 | 2 | 2 | ||||||||
MIRT715386 | TADA3 | transcriptional adaptor 3 | 2 | 2 | ||||||||
MIRT716397 | NPAS1 | neuronal PAS domain protein 1 | 2 | 2 | ||||||||
MIRT725328 | NFASC | neurofascin | 2 | 2 | ||||||||
MIRT725503 | GANAB | glucosidase II alpha subunit | 2 | 2 | ||||||||
MIRT732913 | IRAK2 | interleukin 1 receptor associated kinase 2 | 3 | 0 | ||||||||
MIRT734890 | SMAD3 | SMAD family member 3 | 3 | 0 | ||||||||
MIRT737328 | LINC02476 | long intergenic non-protein coding RNA 2476 | 3 | 0 | ||||||||
MIRT737544 | MALAT1 | metastasis associated lung adenocarcinoma transcript 1 (non-protein coding) | 4 | 0 | ||||||||
MIRT755545 | PAK1 | p21 (RAC1) activated kinase 1 | 3 | 1 |
miRNA-Drug Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
miRNA-Drug Resistance Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|